IRTAL (Integrated RNA-Therapeutic Assembly Line) - Deep Overview

Codename: RNA-Targeting Discovery & Manufacturing Platform | Status: CONCEPT | Classification: UNCLASSIFIED

Overview

**SYSTEM CLASSIFICATION** Integrated High-Throughput RNA-Therapeutic Discovery, Validation, and Synthesis Platform. **PRIMARY MISSION** To establish a unified, continuous-flow architecture for discovering, validating, and manufacturing RNA-targeting therapeutics by closing the gap between bead-based avidity enrichment and true monovalent affinity measurement. **INDUSTRY CHALLENGE** Conventional DNA-encoded library (DEL) screens against RNA targets suffer from high hit-attrition rates because bead-based selections report multivalent avidity rather than true monovalent affinity. Furthermore, DNA tags create non-specific interference on RNA-binding proteins, while fragmented downstream synthesis creates severe manufacturing latency. **HIGH-LEVEL SOLUTIONS** • **Label-Free Monovalent Validation:** Deploys a grating-coupled surface plasmon resonance (GC-SPR) Bio-Disc utilizing 5'-amine RNA coupling and chiral circular dichroism (CD) drift rejection to measure true monovalent Kd values across multi-zone addressable arrays. • **Zero-Shear Acousto-Magnetic Sorting:** Focuses a colloidal DEL matrix to the hydrodynamic zero-shear mid-plane of a precision-dimensioned folded serpentine channel via a high-frequency ultrasonic standing wave, executing continuous binary separation under ultra-low tether tension. • **Photocleavable Colloidal DEL Matrix:** Integrates a large-scale combinatorial library synthesized on monodisperse sub-micron core-shell particles featuring targeted photocleavable linkers for tag-free monovalent re-assay. • **Anhydrous TSA Oligonucleotide Synthesis:** Combines industrial Dynamic Axial Compression (DAC) columns with a closed-loop Thermal Swing Adsorption (TSA) zeolite solvent drying skid to produce kilogram-scale pharmaceutical-grade oligonucleotides with high solvent recovery. **TARGET APPLICATIONS** • **Oncoprotein mRNA Modulation:** Target upstream mRNA 5' UTR internal ribosome entry sites and secondary structures in historically undruggable drivers such as MYC and KRAS. • **Pre-mRNA Splicing Correction:** Mask intronic splicing silencers and repeat-expansion hairpins in SMN2, ALS, and Huntington's Disease using targeted antisense oligonucleotides (ASOs). • **Viral Genome Targeting:** Deploy catalytic RIBOTAC chimeras and ASOs against conserved viral pseudoknots and frameshifting elements. **PROJECTED PERFORMANCE OBJECTIVES** • Discovery Capacity: High-density compound screening through a rapid continuous sorting run followed by label-free monovalent re-assay. • Kinetic Resolution: Real-time, label-free Kd quantification spanning a broad dynamic range. • Force Control: Peak tether tension clamped well below molecular rupture thresholds. • Manufacturing Yield: Kilogram-scale weekly output of high-purity modified RNA with high step-wise coupling efficiency and ultra-low moisture. **PARTNERSHIP & NDA-GATED TECHNICAL BRIEF** • **Development Status:** Master Technical Record and Engineering Audit Complete. • **Collaboration Request:** Seeking co-development, licensing, strategic investment, or clinical manufacturing partnerships. • **Notice:** Detailed serpentine channel dimensions, exact acoustic drive frequencies, Halbach magnetic field gradients, photocleavable linker stoichiometry, specific compound library volumes, and phosphoramidite coupling kinetics are strictly withheld and available only under NDA.

Technical Specifications

  • DESIGNATION: TERRANEX IRTAL
  • DEVELOPMENT STATUS: In Development / Master Audit Complete
  • TECHNICAL REVIEW: NDA Required
  • PRIMARY FUNCTION: Integrated High-Throughput RNA-Therapeutic Discovery & Assembly
  • SYSTEM ARCHITECTURE: Closed-Loop Continuous-Flow Modular Platform (Modules A through D)
  • TECHNOLOGY CATEGORY: Bio-Synthetic Architecture & Nanofluidic Screening Systems
  • CORE PLATFORM: Label-Free Plasmonic Bio-Disc & Acousto-Magnetic Serpentine Sorter
  • INTEGRATION STRATEGY: Avidity-to-Affinity Mapping via Photocleavable DEL Linkers and Label-Free Readout
  • MANUFACTURING PATH: Injection-Molded COC Substrates, Precision CNC Microfluidics, and Industrial DAC Hydraulics
  • SCALABILITY PROFILE: Kilogram-scale weekly production via Thermal Swing Adsorption DAC columns
  • TARGET APPLICATIONS: Oncoprotein mRNA Modulation, Splicing Correction, and Viral RNA Targeting
  • COMMERCIAL PATHWAY: Licensing / Acquisition / Co-Development
  • PARTNERSHIP STATUS: Open
  • INVESTMENT STATUS: Seeking Strategic Partners
  • TECHNOLOGY READINESS: Benchmark Validated & Engineering Audit Complete

Documentation

Targeting human RNA with small molecules and synthetic oligonucleotides represents a major frontier in medicine, yet traditional drug discovery is bottlenecked by the gap between high-throughput screening and biophysical validation. Standard DNA-encoded library (DEL) screens against RNA targets report multivalent contact valency (avidity) rather than true molecular binding affinity, causing candidate compounds to fail when resynthesized off-DNA. The Integrated RNA-Therapeutic Assembly Line (IRTAL) resolves this bottleneck by unifying discovery, monovalent validation, and kilogram-scale manufacturing into a single continuous workflow. Rather than relying on fragmented offline assays, IRTAL integrates four specialized modules: • **Plasmonic Bio-Disc (Module A):** Grating-coupled SPR discs produced on optical disc manufacturing lines deliver label-free kinetic readout across multi-zone addressable arrays. Target RNA is immobilized via 5'-amine coupling to eliminate biotin interference, while chiral gold helicoids suppress common-mode thermal and refractive index drift. • **Anhydrous Oligonucleotide Synthesis (Module B):** Dynamic Axial Compression (DAC) columns operating under high-pressure hydraulic stabilization prevent polymer bed channeling. A closed-loop Thermal Swing Adsorption (TSA) zeolite drying skid maintains ultra-low solvent moisture and recovers acetonitrile, supporting kilogram-scale production of clinical-grade ASOs and RIBOTAC chimeras. • **Colloidal DEL Matrix (Module C):** A large-scale compound library synthesized on sub-micron core-shell particles behaves as a stable colloidal suspension in standard buffer. Targeted photocleavable linkers enable rapid UVA release of candidate compounds for immediate tag-free monovalent validation. • **Acousto-Magnetic Serpentine Sorter (Module D):** A folded serpentine channel utilizes an ultrasonic standing wave to trap target complexes at the hydrodynamic zero-shear plane. A planar NdFeB Halbach array provides gentle magnetic deflection, achieving complete binary separation under ultra-low tether tension. By converting avidity-driven enrichment into label-free, monovalent kinetic measurement before committing to large-scale synthesis, IRTAL establishes a physically grounded, industrial platform for RNA-targeted therapeutics.